室外夜间暴露于光线 (光污染) 与阿尔茨海默病相关
Robin M Voigt1,2,3, Bichun Ouyang4, Ali Keshavarzian1,2,3,5
1Rush Medical College, Rush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center; Chicago, IL, USA.
medRxiv : the preprint server for health sciences
|February 26, 2024
概括
更多的室外夜间光线暴露与阿尔茨海默病 (AD) 患病率的增加有关. 这一环境因素特别与早期发病的阿尔茨海默病有关,这表明需要进一步研究其在疾病发展中的作用.
科学领域:
- 环境流行病学环境流行病学
- 神经退行性疾病 神经退行性疾病
- 公共卫生 公共卫生
背景情况:
- 全球范围内阿尔茨海默病 (AD) 患病率正在上升,寿命延长和环境因素都有所贡献.
- 了解环境对阿尔茨海默氏病原学的影响,对于制定预防策略至关重要.
结论:
- 户外夜间照明暴露成为阿尔茨海默病的潜在环境风险因素.
- 需要进一步的研究来阐明光污染可能影响AD病变的具体机制,特别是在年轻人群中.
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Photoreceptors and Visual Pathways
6.0K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.0K
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189


